Antenatal care
Clinical Guideline
Routine care for
the healthy
pregnant woman
The following guidance is evidence
based.
Developed by the National Collaborating
Centre for Women’s and Children’s Health
Developed at October 2003, valid till
2007
The grading scheme used for the
recommendations (A, B, C, D, good
practice point [GPP] or NICE 2002)
Gestational age assessment:
LMP and ultrasound
Pregnant women should be
offered an early ultrasound
scan to determine
gestational age and to detect
multiple pregnancies.
A
Early ultrasound scan
1.Ensure consistency of gestational
age assessments,
2.Improve the performance of mid-
trimester serum screening for
Down’s syndrome and
3.Reduce the need for induction of
labour after 41 weeks. A
Ideally, scans should be
performed between
10 and 13 weeks and
crown–rump length
measurement used to
determine gestational age.
Gestational age assessment:
LMP and ultrasound
GPP
Pregnant women who present
at or beyond 14 weeks’ gestation
should be offered an ultrasound
scan to estimate gestational age
using head circumference or
bi-parietal diameter.
Gestational age assessment:
LMP and ultrasound
GPP
The majority of women can be
reassured that it is safe to continue
working during pregnancy.
A woman’s occupation during
pregnancy should be ascertained to
identify those at increased risk
through occupational exposure.
Working during pregnancy
D
GPP
Nutritional supplements
Dietary supplementation with folic
acid, before conception and up to
12 weeks’ gestation, reduces the
risk of having a baby with neural
tube defects
(anencephaly& spina bifida).
The recommended dose is
400 micrograms per day.
Folic acid
A
Iron supplementation should not
be offered routinely to all
pregnant women.
It does not benefit the mother’s or
fetus’s health and may have
unpleasant maternal side effects.
Iron
A
Vitamin A supplementation
(intake greater than 700 micrograms)
might be teratogenic and therefore it
should be avoided.
Liver and liver products may also
contain high levels of vitamin A,
consumption of these products should
also be avoided.
Vitamin A
C
There is insufficient evidence to
evaluate the effectiveness of vitamin
D in pregnancy.
In the absence of evidence of
benefit, vitamin D supplementation
should not be offered routinely to
pregnant women.
Vitamin D
A
Food-acquired
infections
Reduce the risk of Listeriosis by:
Drinking only pasteurized or UHT
milk
 Not eating mould-ripened soft cheese
(there is no risk with hard cheeses
such as Cheddar, and processed
cheese).
Not eating uncooked or undercooked
ready-prepared meals. D
Reduce the risk of
Salmonella infection by:
Avoiding raw or partially cooked
eggs or food that may contain
them (such as mayonnaise).
Avoiding raw or partially cooked
meat, especially poultry. D
Prescribed medicines
Few medicines have
been established as
safe to use in
pregnancy. D
Prescription medicines
should be used as little as
possible during pregnancy
and should be limited to
circumstances where the
benefit outweighs the risk.
Prescribed medicines
D
Exercise in pregnancy
Beginning or continuing a
moderate course of
exercise during pregnancy
is not associated with
adverse outcomes. A
Sexual intercourse
in pregnancy
Sexual intercourse in
pregnancy is not known
to be associated with
any adverse outcomes.B
Alcohol in pregnancy
Excess alcohol has an adverse
effect on the fetus.
Therefore it is suggested that
women stop or at least limit
alcohol consumption to no more
than one standard unit per day. C
 There are specific risks of smoking during
pregnancy (such as the risk of having a
baby with low birth weight and preterm).
 The benefits of quitting at any stage
should be emphasized.
 Women who are unable to quit smoking
during pregnancy should be encouraged
to reduce smoking.
Smoking in pregnancy
A
B
Cannabis use in pregnancy
The direct effects of cannabis on the
fetus are uncertain but may be
harmful.
Cannabis use is associated with
smoking, which is known to be
harmful; therefore, women should be
discouraged from using cannabis
during pregnancy. C
Air travel during pregnancy
Pregnant women should be
informed that long-haul air travel
is associated with an increased
risk of venous thrombosis.
Wearing correctly fitted
compression stockings is effective
at reducing the risk. B
Car travel during pregnancy
Pregnant women should be
informed about the correct
use of seat belts
(that is, three-point seatbelts
‘above and below the bump,
not over it’). B
Traveling abroad during pregnancy
If pregnant women are
planning to travel abroad,
they should discuss
considerations such as
flying, vaccinations and
travel insurance. GPP
Management of
common symptoms
of pregnancy
Most cases of nausea and vomiting
in pregnancy will resolve
spontaneously within 16 to 20
weeks of gestation.
Nausea and vomiting are not
usually associated with a poor
pregnancy outcome.
Nausea and vomiting
in early pregnancy
A
Nausea and vomiting in early pregnancy
If a woman requests or would like to
consider treatment, the following
interventions appear to be effective in
reducing symptoms:
non-pharmacological
– ginger
– P6 acupressure
 pharmacological
– antihistamines. A
Heartburn
Women who present with symptoms
of heartburn in pregnancy should be
offered information regarding
lifestyle and diet modification.
Antacids may be offered to women
whose heartburn remains
troublesome
GPP
A
Constipation
Women who present with
constipation in pregnancy
should be offered information
regarding diet modification,
such as bran or wheat fibre
supplementation.
A
Hemorrhoids
Women should be offered
information concerning diet
modification.
If clinical symptoms remain
troublesome, standard
hemorrhoids creams should be
considered. GPP
Varicose veins
Varicose veins are a common
symptom of pregnancy that will not
cause harm and
Compression stockings can
improve the symptoms but will not
prevent varicose veins from
emerging. A
Vaginal discharge
Women should be informed
that an increase in vaginal
discharge is a common
physiological change that
occurs during pregnancy.
GPP
If vaginal discharge is associated
with itching, soreness, offensive
smell or pain on passing urine
there may be an infective cause
and investigation should be
considered.
Vaginal discharge
GPP
A 1-week course of a topical
imidazole is an effective
treatment and should be
considered for vaginal
candidiasis infections in
pregnant women.
Vaginal discharge
A
The effectiveness and safety
of oral treatments for
vaginal candidiasis in
pregnancy is uncertain and
these should not be offered.
Vaginal discharge
GPP
Backache
Women should be informed
that exercising in water,
massage therapy might
help to ease backache
during pregnancy.
A
Clinical examination
of pregnant women
Measurement of weight and
body mass index (BMI)
Maternal weight and height
should be measured at the first
antenatal appointment, and the
woman’s BMI calculated
(weight [kg]/height[m]2).
A
Repeated weighing during
pregnancy should be
confined to circumstances
where clinical management
is likely to be influenced.
Measurement of weight and
body mass index (BMI)
C
Breast examination
Routine breast examination
during antenatal care
is not recommended
for the promotion of
postnatal breastfeeding.
A
Pelvic examination
Routine antenatal pelvic
examination does not accurately
assess gestational age, nor does it
accurately predict preterm birth
or cephalopelvic disproportion.
So, it is not recommended. B
Screening for
hematological
conditions
Anemia
Pregnant women should be offered
screening for anaemia.
Screening should take place early
in pregnancy (at the first
appointment) and at 28 weeks.
This allows enough time for
treatment if anaemia is detected.B
Hemoglobin levels outside the
normal range for pregnancy
(that is, 11 g/dl at first contact and
10.5 g/dl at 28 weeks)
should be investigated and
iron supplementation considered
if indicated.
Anemia
A
Blood grouping and
red cell alloantibodies
Women should be offered
testing for blood group
and RhD status in early
pregnancy.
B
If a pregnant woman is RhD-
negative, offer partner testing
to determine whether the
administration of anti-D
prophylaxis is necessary.
B
Blood grouping and
red cell alloantibodies
It is recommended that routine
antenatal anti-D prophylaxis
is offered to all non-sensitized
pregnant women who are RhD
negative.
Blood grouping and
red cell alloantibodies
NICE 2002
Women should be screened for
atypical red cell alloantibodies
in early pregnancy and again
at 28 weeks regardless of their
RhD status.
Blood grouping and
red cell alloantibodies
D
Pregnant women with clinically
significant atypical red cell
alloantibodies should be offered
referral to a specialist centre for
further investigation and advice on
subsequent antenatal management.
Blood grouping and
red cell alloantibodies
GPP
Screening for
fetal anomalies
Screening for
structural anomalies
Pregnant women should be offered an
ultrasound scan
to screen for structural anomalies,
ideally between 18 and 20 weeks’
gestation, by an appropriately trained
sonographer and with equipment of
an appropriate standard. A
Screening for Down’s syndrome
Pregnant women should be
offered screening for Down’s
syndrome with a test which
provides the current standard
of a detection rate above 60%
and a false-positive rate of less
than 5%. B
The following tests meet this standard:
from 11 to 14 weeks
– nuchal translucency (NT)
– the combined test (NT, hCG and PAPP-A)
from 14 to 20 weeks
– the triple test (hCG, AFP and uE3)
– the quadruple test (hCG, AFP, uE3,
inhibin A)
B
Screening for
infections
Asymptomatic bacteriuria
Pregnant women should be offered
routine screening for asymptomatic
bacteriuria by midstream urine
culture early in pregnancy.
Identification and treatment of
asymptomatic bacteriuria reduces the
risk of preterm birth. A
Asymptomatic bacterial vaginosis
Pregnant women should not be offered
routine screening for bacterial
vaginosis because the evidence
suggests that the identification and
treatment of asymptomatic bacterial
vaginosis does not lower the risk for
preterm birth and other adverse
reproductive outcomes. A
Chlamydia trachomatis
Pregnant women should
not be offered routine screening
for asymptomatic chlamydia
because there is insufficient
evidence on its effectiveness and
cost effectiveness.
C
Cytomegalovirus
The available evidence does
not support routine
cytomegalovirus screening
in pregnant women and it
should not be offered.
B
Hepatitis B virus
Serological screening for hepatitis
B virus should be offered to
pregnant women
So that effective postnatal
intervention can be offered to
infected women to decrease the risk
of mother-to-child-transmission. A
Hepatitis C virus
Pregnant women should
not be offered routine screening
for hepatitis C virus because
there is insufficient evidence on
its effectiveness and cost
effectiveness. C
HIV infection
Pregnant women should be offered
screening for HIV infection early
in antenatal care because
appropriate antenatal
interventions can reduce
mother-to-child transmission of
HIV infection. D
Rubella
Rubella-susceptibility screening should
be offered early in antenatal care to
identify women at risk of contracting
rubella infection and to enable
vaccination in the postnatal period for
the protection of future pregnancies.
B
Streptococcus group B
Pregnant women should not be
offered routine antenatal
screening for group B
streptococcus (GBS)
because evidence of its clinical
effectiveness and cost effectiveness
remains uncertain. C
Syphilis
Screening for syphilis should be
offered to all pregnant women at
an early stage in antenatal care
because treatment of syphilis is
beneficial to the mother and
fetus. B
Toxoplasmosis
Routine antenatal serological
screening for toxoplasmosis
should not be offered because
the harms of screening may
outweigh the potential
benefits. B
 Pregnant women should be informed of primary
prevention measures to avoid toxoplasmosis
infection, such as:
1. Washing hands before handling food
2. Thoroughly washing all fruit and
vegetables, before eating
3. Thoroughly cooking raw meats
4. Wearing gloves and thoroughly washing
hands after handling soil and gardening
5. Avoiding cat faeces in cat litter or in soil.
Toxoplasmosis
C
Screening for
clinical conditions
Gestational diabetes mellitus
The evidence does not
support routine screening
for gestational diabetes
mellitus and therefore
It should not be offered. B
Pre-eclampsia
At first contact a woman’s
level of risk for pre-eclampsia
should be evaluated
so that a plan for her
subsequent schedule of
antenatal appointments can
be formulated. C
Developing pre-eclampsia during a
pregnancy is increased in women who:
1. are nulliparous
2. are aged 40 or older
3. have a family history of pre-eclampsia
4. have a prior history of pre-eclampsia
5. have a body mass index (BMI) at or above 35
at first contact
6. have a multiple pregnancy or pre-existing
vascular disease (for example, hypertension or
diabetes).
C
Whenever blood pressure is
measured in pregnancy a
urine sample should be
tested at the same time for
proteinuria.
Pre-eclampsia
C
 Pregnant women should be informed of the
symptoms of advanced pre-eclampsia
because these may be associated with poorer
pregnancy outcomes for the mother or baby.
 Symptoms include headache; problems with
vision, such as blurring or flashing before the
eyes; bad pain just below the ribs; vomiting
and sudden swelling of face, hands or feet.
Pre-eclampsia
D
Preterm birth
Routine vaginal examination
to assess the cervix
is not an effective method
of predicting preterm birth
and should not be offered.
A
Although cervical shortening identified
by Transvaginal ultrasound and
increased levels of fetal fibronectin
are associated with an increased risk
for preterm birth,
the evidence does not indicate that
this information improves outcomes.
Preterm birth
B
Neither routine antenatal cervical
assessment by transvaginal
ultrasound nor the measurement
of fetal fibronectin
should be used to predict preterm
birth in healthy pregnant women.
Preterm birth
B
Placenta praevia
 Because most low-lying placentas
detected at a 20-week anomaly scan will
resolve by the time the baby is born,
only a woman whose placenta extends
over the internal cervical os should be
offered another Tran abdominal scan at
36 weeks.
 If the transabdominal scan is unclear,
a transvaginal scan should be offered.
C
Fetal growth and
well-being
Abdominal palpation for
fetal presentation
Fetal presentation should be
assessed by abdominal
palpation at 36 weeks or later,
when presentation is likely to
influence the plans for the
birth. C
Routine assessment of presentation by
abdominal palpation
should not be offered before 36 weeks
because it is not always accurate and
may be uncomfortable.
Suspected fetal malpresentation
should be confirmed by ultrasound.
Abdominal palpation for
fetal presentation
C
Measurement of
symphysis–fundal distance
Pregnant women should be offered
estimation of fetal size at each antenatal
appointment to detect small- or large-for
gestational- age infants.
Symphysis–fundal height should be
measured and plotted at each antenatal
appointment.
A
Routine monitoring of
fetal movements
Routine formal
fetal-movement
counting
should not be offered.
A
Auscultation of fetal heart
Auscultation of the fetal heart
may confirm that the fetus is
alive but is unlikely to have
any predictive value
and routine listening is
therefore not recommended.
D
When requested by the
mother, auscultation
of the fetal heart may
provide reassurance.
Auscultation of fetal heart
D
Cardiotocography
The evidence does not support the
routine use of antenatal electronic
fetal heart rate monitoring
(cardiotocography) for fetal
assessment in women with an
uncomplicated pregnancy and
therefore it should not be offered.
A
Ultrasound assessment
in the third trimester
The evidence does not support
the routine use of ultrasound
scanning after 24 weeks’
gestation and therefore it
should not be offered. A
Umbilical artery
Doppler ultrasound
The use of umbilical artery
Doppler ultrasound for the
prediction of fetal growth
restriction should not be
offered routinely. A
The use of uterine artery
Doppler ultrasound for the
prediction of pre eclampsia
should not be offered
routinely.
Uterine artery
Doppler ultrasound
B
Pregnancy after 41 weeks
Prior to formal induction of
labour, women should be offered a
vaginal examination for membrane
sweeping.
Women with uncomplicated
pregnancies should be offered
induction of labour beyond 41
weeks.
A
Breech presentation at term
 All women who have an uncomplicated
singleton breech pregnancy at 36 weeks’
gestation should be offered external cephalic
version (ECV).
 Exceptions include :
1. women in labour, and
2. a uterine scar or abnormality;
3. fetal compromise;
4. ruptured membranes;
5. vaginal bleeding.
A
Antenatal Care Guideline- gestational  Age Assessment,Early USG, Nutritional Supplements,, Food Acquired Infections,medicine, alcohol,smoking, Sexual Intercose avoid, Exercise, Clinical Screening in PPT

Antenatal Care Guideline- gestational Age Assessment,Early USG, Nutritional Supplements,, Food Acquired Infections,medicine, alcohol,smoking, Sexual Intercose avoid, Exercise, Clinical Screening in PPT

  • 1.
  • 2.
    Routine care for thehealthy pregnant woman
  • 3.
    The following guidanceis evidence based. Developed by the National Collaborating Centre for Women’s and Children’s Health Developed at October 2003, valid till 2007 The grading scheme used for the recommendations (A, B, C, D, good practice point [GPP] or NICE 2002)
  • 8.
    Gestational age assessment: LMPand ultrasound Pregnant women should be offered an early ultrasound scan to determine gestational age and to detect multiple pregnancies. A
  • 9.
    Early ultrasound scan 1.Ensureconsistency of gestational age assessments, 2.Improve the performance of mid- trimester serum screening for Down’s syndrome and 3.Reduce the need for induction of labour after 41 weeks. A
  • 10.
    Ideally, scans shouldbe performed between 10 and 13 weeks and crown–rump length measurement used to determine gestational age. Gestational age assessment: LMP and ultrasound GPP
  • 11.
    Pregnant women whopresent at or beyond 14 weeks’ gestation should be offered an ultrasound scan to estimate gestational age using head circumference or bi-parietal diameter. Gestational age assessment: LMP and ultrasound GPP
  • 12.
    The majority ofwomen can be reassured that it is safe to continue working during pregnancy. A woman’s occupation during pregnancy should be ascertained to identify those at increased risk through occupational exposure. Working during pregnancy D GPP
  • 13.
  • 14.
    Dietary supplementation withfolic acid, before conception and up to 12 weeks’ gestation, reduces the risk of having a baby with neural tube defects (anencephaly& spina bifida). The recommended dose is 400 micrograms per day. Folic acid A
  • 15.
    Iron supplementation shouldnot be offered routinely to all pregnant women. It does not benefit the mother’s or fetus’s health and may have unpleasant maternal side effects. Iron A
  • 16.
    Vitamin A supplementation (intakegreater than 700 micrograms) might be teratogenic and therefore it should be avoided. Liver and liver products may also contain high levels of vitamin A, consumption of these products should also be avoided. Vitamin A C
  • 17.
    There is insufficientevidence to evaluate the effectiveness of vitamin D in pregnancy. In the absence of evidence of benefit, vitamin D supplementation should not be offered routinely to pregnant women. Vitamin D A
  • 18.
  • 19.
    Reduce the riskof Listeriosis by: Drinking only pasteurized or UHT milk  Not eating mould-ripened soft cheese (there is no risk with hard cheeses such as Cheddar, and processed cheese). Not eating uncooked or undercooked ready-prepared meals. D
  • 20.
    Reduce the riskof Salmonella infection by: Avoiding raw or partially cooked eggs or food that may contain them (such as mayonnaise). Avoiding raw or partially cooked meat, especially poultry. D
  • 21.
    Prescribed medicines Few medicineshave been established as safe to use in pregnancy. D
  • 22.
    Prescription medicines should beused as little as possible during pregnancy and should be limited to circumstances where the benefit outweighs the risk. Prescribed medicines D
  • 23.
    Exercise in pregnancy Beginningor continuing a moderate course of exercise during pregnancy is not associated with adverse outcomes. A
  • 24.
    Sexual intercourse in pregnancy Sexualintercourse in pregnancy is not known to be associated with any adverse outcomes.B
  • 25.
    Alcohol in pregnancy Excessalcohol has an adverse effect on the fetus. Therefore it is suggested that women stop or at least limit alcohol consumption to no more than one standard unit per day. C
  • 26.
     There arespecific risks of smoking during pregnancy (such as the risk of having a baby with low birth weight and preterm).  The benefits of quitting at any stage should be emphasized.  Women who are unable to quit smoking during pregnancy should be encouraged to reduce smoking. Smoking in pregnancy A B
  • 27.
    Cannabis use inpregnancy The direct effects of cannabis on the fetus are uncertain but may be harmful. Cannabis use is associated with smoking, which is known to be harmful; therefore, women should be discouraged from using cannabis during pregnancy. C
  • 28.
    Air travel duringpregnancy Pregnant women should be informed that long-haul air travel is associated with an increased risk of venous thrombosis. Wearing correctly fitted compression stockings is effective at reducing the risk. B
  • 29.
    Car travel duringpregnancy Pregnant women should be informed about the correct use of seat belts (that is, three-point seatbelts ‘above and below the bump, not over it’). B
  • 30.
    Traveling abroad duringpregnancy If pregnant women are planning to travel abroad, they should discuss considerations such as flying, vaccinations and travel insurance. GPP
  • 31.
  • 32.
    Most cases ofnausea and vomiting in pregnancy will resolve spontaneously within 16 to 20 weeks of gestation. Nausea and vomiting are not usually associated with a poor pregnancy outcome. Nausea and vomiting in early pregnancy A
  • 33.
    Nausea and vomitingin early pregnancy If a woman requests or would like to consider treatment, the following interventions appear to be effective in reducing symptoms: non-pharmacological – ginger – P6 acupressure  pharmacological – antihistamines. A
  • 34.
    Heartburn Women who presentwith symptoms of heartburn in pregnancy should be offered information regarding lifestyle and diet modification. Antacids may be offered to women whose heartburn remains troublesome GPP A
  • 35.
    Constipation Women who presentwith constipation in pregnancy should be offered information regarding diet modification, such as bran or wheat fibre supplementation. A
  • 36.
    Hemorrhoids Women should beoffered information concerning diet modification. If clinical symptoms remain troublesome, standard hemorrhoids creams should be considered. GPP
  • 37.
    Varicose veins Varicose veinsare a common symptom of pregnancy that will not cause harm and Compression stockings can improve the symptoms but will not prevent varicose veins from emerging. A
  • 38.
    Vaginal discharge Women shouldbe informed that an increase in vaginal discharge is a common physiological change that occurs during pregnancy. GPP
  • 39.
    If vaginal dischargeis associated with itching, soreness, offensive smell or pain on passing urine there may be an infective cause and investigation should be considered. Vaginal discharge GPP
  • 40.
    A 1-week courseof a topical imidazole is an effective treatment and should be considered for vaginal candidiasis infections in pregnant women. Vaginal discharge A
  • 41.
    The effectiveness andsafety of oral treatments for vaginal candidiasis in pregnancy is uncertain and these should not be offered. Vaginal discharge GPP
  • 42.
    Backache Women should beinformed that exercising in water, massage therapy might help to ease backache during pregnancy. A
  • 43.
  • 44.
    Measurement of weightand body mass index (BMI) Maternal weight and height should be measured at the first antenatal appointment, and the woman’s BMI calculated (weight [kg]/height[m]2). A
  • 45.
    Repeated weighing during pregnancyshould be confined to circumstances where clinical management is likely to be influenced. Measurement of weight and body mass index (BMI) C
  • 46.
    Breast examination Routine breastexamination during antenatal care is not recommended for the promotion of postnatal breastfeeding. A
  • 47.
    Pelvic examination Routine antenatalpelvic examination does not accurately assess gestational age, nor does it accurately predict preterm birth or cephalopelvic disproportion. So, it is not recommended. B
  • 48.
  • 49.
    Anemia Pregnant women shouldbe offered screening for anaemia. Screening should take place early in pregnancy (at the first appointment) and at 28 weeks. This allows enough time for treatment if anaemia is detected.B
  • 50.
    Hemoglobin levels outsidethe normal range for pregnancy (that is, 11 g/dl at first contact and 10.5 g/dl at 28 weeks) should be investigated and iron supplementation considered if indicated. Anemia A
  • 51.
    Blood grouping and redcell alloantibodies Women should be offered testing for blood group and RhD status in early pregnancy. B
  • 52.
    If a pregnantwoman is RhD- negative, offer partner testing to determine whether the administration of anti-D prophylaxis is necessary. B Blood grouping and red cell alloantibodies
  • 53.
    It is recommendedthat routine antenatal anti-D prophylaxis is offered to all non-sensitized pregnant women who are RhD negative. Blood grouping and red cell alloantibodies NICE 2002
  • 54.
    Women should bescreened for atypical red cell alloantibodies in early pregnancy and again at 28 weeks regardless of their RhD status. Blood grouping and red cell alloantibodies D
  • 55.
    Pregnant women withclinically significant atypical red cell alloantibodies should be offered referral to a specialist centre for further investigation and advice on subsequent antenatal management. Blood grouping and red cell alloantibodies GPP
  • 56.
  • 57.
    Screening for structural anomalies Pregnantwomen should be offered an ultrasound scan to screen for structural anomalies, ideally between 18 and 20 weeks’ gestation, by an appropriately trained sonographer and with equipment of an appropriate standard. A
  • 58.
    Screening for Down’ssyndrome Pregnant women should be offered screening for Down’s syndrome with a test which provides the current standard of a detection rate above 60% and a false-positive rate of less than 5%. B
  • 59.
    The following testsmeet this standard: from 11 to 14 weeks – nuchal translucency (NT) – the combined test (NT, hCG and PAPP-A) from 14 to 20 weeks – the triple test (hCG, AFP and uE3) – the quadruple test (hCG, AFP, uE3, inhibin A) B
  • 60.
  • 61.
    Asymptomatic bacteriuria Pregnant womenshould be offered routine screening for asymptomatic bacteriuria by midstream urine culture early in pregnancy. Identification and treatment of asymptomatic bacteriuria reduces the risk of preterm birth. A
  • 62.
    Asymptomatic bacterial vaginosis Pregnantwomen should not be offered routine screening for bacterial vaginosis because the evidence suggests that the identification and treatment of asymptomatic bacterial vaginosis does not lower the risk for preterm birth and other adverse reproductive outcomes. A
  • 63.
    Chlamydia trachomatis Pregnant womenshould not be offered routine screening for asymptomatic chlamydia because there is insufficient evidence on its effectiveness and cost effectiveness. C
  • 64.
    Cytomegalovirus The available evidencedoes not support routine cytomegalovirus screening in pregnant women and it should not be offered. B
  • 65.
    Hepatitis B virus Serologicalscreening for hepatitis B virus should be offered to pregnant women So that effective postnatal intervention can be offered to infected women to decrease the risk of mother-to-child-transmission. A
  • 66.
    Hepatitis C virus Pregnantwomen should not be offered routine screening for hepatitis C virus because there is insufficient evidence on its effectiveness and cost effectiveness. C
  • 67.
    HIV infection Pregnant womenshould be offered screening for HIV infection early in antenatal care because appropriate antenatal interventions can reduce mother-to-child transmission of HIV infection. D
  • 68.
    Rubella Rubella-susceptibility screening should beoffered early in antenatal care to identify women at risk of contracting rubella infection and to enable vaccination in the postnatal period for the protection of future pregnancies. B
  • 69.
    Streptococcus group B Pregnantwomen should not be offered routine antenatal screening for group B streptococcus (GBS) because evidence of its clinical effectiveness and cost effectiveness remains uncertain. C
  • 70.
    Syphilis Screening for syphilisshould be offered to all pregnant women at an early stage in antenatal care because treatment of syphilis is beneficial to the mother and fetus. B
  • 71.
    Toxoplasmosis Routine antenatal serological screeningfor toxoplasmosis should not be offered because the harms of screening may outweigh the potential benefits. B
  • 72.
     Pregnant womenshould be informed of primary prevention measures to avoid toxoplasmosis infection, such as: 1. Washing hands before handling food 2. Thoroughly washing all fruit and vegetables, before eating 3. Thoroughly cooking raw meats 4. Wearing gloves and thoroughly washing hands after handling soil and gardening 5. Avoiding cat faeces in cat litter or in soil. Toxoplasmosis C
  • 73.
  • 74.
    Gestational diabetes mellitus Theevidence does not support routine screening for gestational diabetes mellitus and therefore It should not be offered. B
  • 75.
    Pre-eclampsia At first contacta woman’s level of risk for pre-eclampsia should be evaluated so that a plan for her subsequent schedule of antenatal appointments can be formulated. C
  • 76.
    Developing pre-eclampsia duringa pregnancy is increased in women who: 1. are nulliparous 2. are aged 40 or older 3. have a family history of pre-eclampsia 4. have a prior history of pre-eclampsia 5. have a body mass index (BMI) at or above 35 at first contact 6. have a multiple pregnancy or pre-existing vascular disease (for example, hypertension or diabetes). C
  • 77.
    Whenever blood pressureis measured in pregnancy a urine sample should be tested at the same time for proteinuria. Pre-eclampsia C
  • 78.
     Pregnant womenshould be informed of the symptoms of advanced pre-eclampsia because these may be associated with poorer pregnancy outcomes for the mother or baby.  Symptoms include headache; problems with vision, such as blurring or flashing before the eyes; bad pain just below the ribs; vomiting and sudden swelling of face, hands or feet. Pre-eclampsia D
  • 79.
    Preterm birth Routine vaginalexamination to assess the cervix is not an effective method of predicting preterm birth and should not be offered. A
  • 80.
    Although cervical shorteningidentified by Transvaginal ultrasound and increased levels of fetal fibronectin are associated with an increased risk for preterm birth, the evidence does not indicate that this information improves outcomes. Preterm birth B
  • 81.
    Neither routine antenatalcervical assessment by transvaginal ultrasound nor the measurement of fetal fibronectin should be used to predict preterm birth in healthy pregnant women. Preterm birth B
  • 82.
    Placenta praevia  Becausemost low-lying placentas detected at a 20-week anomaly scan will resolve by the time the baby is born, only a woman whose placenta extends over the internal cervical os should be offered another Tran abdominal scan at 36 weeks.  If the transabdominal scan is unclear, a transvaginal scan should be offered. C
  • 83.
  • 84.
    Abdominal palpation for fetalpresentation Fetal presentation should be assessed by abdominal palpation at 36 weeks or later, when presentation is likely to influence the plans for the birth. C
  • 85.
    Routine assessment ofpresentation by abdominal palpation should not be offered before 36 weeks because it is not always accurate and may be uncomfortable. Suspected fetal malpresentation should be confirmed by ultrasound. Abdominal palpation for fetal presentation C
  • 86.
    Measurement of symphysis–fundal distance Pregnantwomen should be offered estimation of fetal size at each antenatal appointment to detect small- or large-for gestational- age infants. Symphysis–fundal height should be measured and plotted at each antenatal appointment. A
  • 87.
    Routine monitoring of fetalmovements Routine formal fetal-movement counting should not be offered. A
  • 88.
    Auscultation of fetalheart Auscultation of the fetal heart may confirm that the fetus is alive but is unlikely to have any predictive value and routine listening is therefore not recommended. D
  • 89.
    When requested bythe mother, auscultation of the fetal heart may provide reassurance. Auscultation of fetal heart D
  • 90.
    Cardiotocography The evidence doesnot support the routine use of antenatal electronic fetal heart rate monitoring (cardiotocography) for fetal assessment in women with an uncomplicated pregnancy and therefore it should not be offered. A
  • 91.
    Ultrasound assessment in thethird trimester The evidence does not support the routine use of ultrasound scanning after 24 weeks’ gestation and therefore it should not be offered. A
  • 92.
    Umbilical artery Doppler ultrasound Theuse of umbilical artery Doppler ultrasound for the prediction of fetal growth restriction should not be offered routinely. A
  • 93.
    The use ofuterine artery Doppler ultrasound for the prediction of pre eclampsia should not be offered routinely. Uterine artery Doppler ultrasound B
  • 94.
    Pregnancy after 41weeks Prior to formal induction of labour, women should be offered a vaginal examination for membrane sweeping. Women with uncomplicated pregnancies should be offered induction of labour beyond 41 weeks. A
  • 95.
    Breech presentation atterm  All women who have an uncomplicated singleton breech pregnancy at 36 weeks’ gestation should be offered external cephalic version (ECV).  Exceptions include : 1. women in labour, and 2. a uterine scar or abnormality; 3. fetal compromise; 4. ruptured membranes; 5. vaginal bleeding. A